Simvastatin

Evidence Level: L5

Predicted Indications: 5

Simvastatin

Pharmacist Assessment Report

Simvastatin: From Hyperlipidaemia and Cerebrovascular Disease to brain stem infarction

One-Sentence Summary

Simvastatin is a statin originally used to treat hyperlipidaemia (including homozygous familial hypercholesterolaemia), atherosclerosis and stroke-related disorders. The TxGNN model predicts it may be effective for familial hypercholesterolaemia, with 9 clinical trials and 19 publications currently supporting this direction. Note that this is effectively an on-label or near-label use rather than true repurposing, because homozygous familial hypercholesterolaemia is already a listed original indication.

Quick Overview

Item	Content
Original Indication	Hyperlipidaemia, including homozygous familial hypercholesterolaemia, atherosclerosis and stroke-related disorders (the ARTG entry in the data compiled for this report has no indication text)
Predicted New Indication	Familial hypercholesterolaemia
TxGNN Prediction Score	0.9941
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Proceed with Guardrails

Evidence level note: the L1 rating comes from the data compiled for this report. Strictly, the completed Phase 3 trials are mostly combination or background-therapy studies (see below), so the direct evidence for simvastatin alone is weaker than L1 suggests.

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on well-established pharmacology, simvastatin inhibits HMG-CoA reductase. This lowers cholesterol synthesis in the liver and upregulates LDL receptors, which increases clearance of LDL cholesterol from the blood.

Familial hypercholesterolaemia is an inherited condition in which LDL clearance is impaired. Simvastatin’s mechanism directly targets this problem. Homozygous familial hypercholesterolaemia is already among its original indications, so extending to familial hypercholesterolaemia generally (including heterozygous forms) is a small step. Its efficacy depends on some residual LDL receptor function.

Clinical Trial Evidence

Many of the trials below test another drug (ezetimibe, alirocumab or an investigational agent) with simvastatin as part of the regimen or as background therapy.

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00552097	Phase 3	Completed	720	ENHANCE: ezetimibe plus high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in heterozygous FH
NCT00129402	Phase 3	Completed	248	Ezetimibe coadministered with simvastatin vs simvastatin alone in adolescents (10-17 years) with heterozygous FH
NCT03884452	Phase 3	Completed	50	Ezetimibe added to atorvastatin or simvastatin in homozygous FH (efficacy and safety)
NCT03885921	Phase 3	Completed	44	24-month open-label extension of ezetimibe with atorvastatin or simvastatin in homozygous FH (long-term safety)
NCT00654446	Phase 3	Completed	442	Renal effects of rosuvastatin vs simvastatin in Type IIa/IIb dyslipidaemia, including heterozygous FH (relevance limited)
NCT01709500	Phase 3	Completed	249	Alirocumab vs placebo in heterozygous FH not controlled on lipid-modifying therapy (simvastatin likely background)
NCT03510884	Phase 3	Completed	153	Alirocumab vs placebo in children and adolescents with heterozygous FH (indirect evidence)
NCT03510715	Phase 3	Completed	18	Open-label alirocumab in children and adolescents with homozygous FH (simvastatin at most background)
NCT01890967	Phase 2	Completed	527	Dose-ranging study of LY3015014 in primary hypercholesterolaemia (simvastatin at most background)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41824590	2026	Guideline	J Am Coll Cardiol	2026 ACC/AHA dyslipidaemia management guideline, replacing the 2018 cholesterol guideline
41824552	2026	Guideline	Circulation	Same 2026 ACC/AHA dyslipidaemia guideline (joint publication)
18376000	2008	Clinical trial (ENHANCE)	N Engl J Med	Simvastatin with or without ezetimibe in FH, assessing progression of atherosclerosis
31696945	2019	Systematic review	Cochrane Database Syst Rev	Statins for children with familial hypercholesterolaemia
28685504	2017	Systematic review	Cochrane Database Syst Rev	Statins for children with familial hypercholesterolaemia (earlier update)
12908847	2003	Review	Drug Saf	Benefits and risks of simvastatin in familial hypercholesterolaemia
15794711	2005	Review	Expert Opin Drug Saf	Benefits and risks assessment of simvastatin in familial hypercholesterolaemia
18940534	2008	Clinical study	J Am Coll Cardiol	Efficacy and safety of ezetimibe plus simvastatin in adolescents with heterozygous FH
21173733	2010	Clinical study	Int Angiol	Long-term ezetimibe/simvastatin treatment in FH
2679083	1989	Clinical study	Am J Med	Simvastatin 20 mg lowered LDL cholesterol by 38% at 8 weeks, and 40 mg by 42% after a further 16 weeks, in FH

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 13373W	Simvar 20	Tablet 20 mg (oral)	Not specified in the data compiled for this report

Safety Considerations

Contraindication-related conditions (from the knowledge graph, not product label text): pancreatitis, liver disease, gallbladder disease, thrombocytopenia, hyperglycaemia, peptic ulcer disease, myopathy and other muscle diseases, rhabdomyolysis, diabetes mellitus, diabetic ketoacidosis, gout, blood coagulation disease, acute coronary syndrome, coronary artery disease and myocardial infarction, among others. These are model-derived associations and need verification against the label.
Drug interactions (100 recorded; examples):
- Major: amiodarone, amlodipine, fenofibrate.
- Moderate: zidovudine, paclitaxel, nifedipine, omeprazole, aprepitant, apalutamide, alpelisib, ethanol, among others.
- Strong CYP3A4 inhibitors raise simvastatin exposure and the risk of myopathy and rhabdomyolysis.
Paediatric use: dosing and monitoring need particular care in adolescents.

Please refer to the TGA-approved Product Information (PI) for the full warnings, contraindications and dose limits.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanism is well established, and several completed Phase 3 trials, plus guidelines and Cochrane reviews, support simvastatin in familial hypercholesterolaemia. Most trial evidence is for combination therapy or background use, and the indication substantially overlaps with an existing one, so this is not a novel repurposing.

To proceed, the following is needed:

The approved indication text and PI warnings and contraindications for the Australian product (ARTG 13373W)
Confirmation of the mechanism of action from a primary source such as DrugBank
A monitoring plan for myopathy, liver function and CYP3A4 interactions
Paediatric dosing and monitoring guidance if adolescents are included

Other Predicted Indications (Brief Note)

Predicted Indication	Evidence Level	Decision	Comment
Hypercholesterolaemia, autosomal dominant	L1	Proceed with Guardrails	Overlaps with familial hypercholesterolaemia; same trials and reviews apply
HIV infection	L3	Research Question	Trials are pharmacokinetic interaction studies only; any use would be for HIV-associated dyslipidaemia, and simvastatin is generally avoided with boosted antiretrovirals
Brain stem infarction	L5	Hold	Only preclinical literature, with simvastatin not the focus
Simian immunodeficiency virus infection	L4	Hold	Only a non-human primate study, with no human indication
CETP deficiency, CYP7A1-deficiency hypercholesterolaemia, ABri amyloidosis, a rare neurodevelopmental disorder, fibroma of prostate	L5	Hold	Model prediction only; no trials or literature

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.